title: Cost-effectiveness of voluntary HIV screening in Russia.
abstract: Russia has one of the world's fastest growing HIV epidemics, and HIV screening has been widespread. Whether such screening is an effective use of resources is unclear. We used epidemiologic and economic data from Russia to develop a Markov model to estimate costs, quality of life and survival associated with a voluntary HIV screening programme compared with no screening in Russia. We measured discounted lifetime health-care costs and quality-adjusted life years (QALYs) gained. We varied our inputs in sensitivity analysis. Early identification of HIV through screening provided a substantial benefit to persons with HIV, increasing life expectancy by 2.1 years and 1.7 QALYs. At a base-case prevalence of 1.2%, once-per-lifetime screening cost $13,396 per QALY gained, exclusive of benefit from reduced transmission. Cost-effectiveness of screening remained favourable until prevalence dropped below 0.04%. When HIV-transmission-related costs and benefits were included, once-per-lifetime screening cost $6910 per QALY gained and screening every two years cost $27,696 per QALY gained. An important determinant of the cost-effectiveness of screening was effectiveness of counselling about risk reduction. Early identification of HIV infection through screening in Russia is effective and cost-effective in all but the lowest prevalence groups.
authors.affiliation: Center for Primary Care and Outcomes Research, Stanford University School of Medicine, Stanford, CA 94305-6019, USA. swati.tole@gmail.com
authors.forename: S P
authors.initials: SP
authors.lastname: Tole
authors.forename: G D
authors.initials: GD
authors.lastname: Sanders
authors.forename: A M
authors.initials: AM
authors.lastname: Bayoumi
authors.forename: C M
authors.initials: CM
authors.lastname: Galvin
authors.forename: T N
authors.initials: TN
authors.lastname: Vinichenko
authors.forename: M L
authors.initials: ML
authors.lastname: Brandeau
authors.forename: D K
authors.initials: DK
authors.lastname: Owens
mesh_terms: D015492:AIDS Serodiagnosis / Q000191:economics*; D000293:Adolescent; D000328:Adult; D003362:Cost-Benefit Analysis; D015483:HIV Antibodies / Q000097:blood; D015658:HIV Infections / Q000175:diagnosis* / Q000453:epidemiology / Q000517:prevention & control / Q000635:transmission; D006801:Humans; D008390:Markov Chains; D008403:Mass Screening / Q000191:economics* / Q000379:methods; D008875:Middle Aged; D015995:Prevalence; D011788:Quality of Life; D012426:Russia / Q000453:epidemiology; D035141:Voluntary Programs / Q000191:economics* / Q000706:statistics & numerical data; D055815:Young Adult
chemical_list: D015483:HIV Antibodies